Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

被引：5
|
作者：
Vacas, Eva [1 ]
Munoz-Moreno, Laura [1 ]
Fernandez-Martinez, Ana B. [1 ]
Bajo, Ana M. [1 ]
Sanchez-Chapado, Manuel [2 ,3 ]
Prieto, Juan C. [1 ]
Carmena, Maria J. [1 ]
机构：
[1] Univ Alcala, Unit Biochem & Mol Biol, Dept Syst Biol, Alcala De Henares 28871, Spain
[2] Univ Alcala, Surg Unit, Dept Surg & Med & Social Sci, Alcala De Henares 28871, Spain
[3] Principe Asturias Hosp, Dept Urol, Alcala De Henares 28871, Spain
来源：
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2014年 / 53卷
关键词：
VIP; PI3K; VEGF; p53; Renal cell carcinoma; VASOACTIVE-INTESTINAL-PEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; OXIDATIVE STRESS; CANCER; STIMULATION; RECEPTORS; THERAPY; MODELS; TARGET;
D O I：
10.1016/j.biocel.2014.05.036
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Vasoactive intestinal peptide (VIP) decreases cell proliferation through PI3K signalling and prevents tumour progression in clear renal cell carcinoma (RCC). Here we analyzed the signalling pathways that mediate such VIP effects by using human RCC A498 cells. The effects of treatment with 1 mu M VIP and/or specific protein kinase inhibitors such as H89, Wortmannin and PD98059 were studied by cell adhesion assay, ELISA of VEGF165 and ROS production assays. Semiquantitative RT-PCR and western blot were performed to study p53 expression. VIP increased cell adhesion and ROS production, and decreased VEGF165 secretion through PI3K signalling. Moreover, VIP increased nuclear expression of tumour suppressor p53. VIP effects could be blocked by cell incubation with a specific p53 inhibitor, cyclin pifithrin-alpha, hydrobromide (CPFT-alpha H). In conclusion, this study provides a p53-dependent mechanism by which VIP regulates cell proliferation in RCC development. It supports a potential usefulness of VIP in new therapies of RCC. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：295 / 301
页数：7
相关论文
共 50 条
  • [1] P53 and survivin expression in renal cell carcinoma
    Radovanovic, Milan
    Petrovic, Milos
    Santric, Veljko
    Milojevic, Bogomir
    Zubelic, Aleksa
    Isakovic, Aleksandra
    UROLOGY ANNALS, 2023, 15 (02) : 186 - 190
  • [2] Expression of p53 isoforms in renal cell carcinoma
    Song Wei
    Huo Shi-wei
    Lue Jia-ju
    Liu Zheng
    Fang Xiao-lei
    Jin Xun-bo
    Yuan Ming-zhen
    CHINESE MEDICAL JOURNAL, 2009, 122 (08) : 921 - 926
  • [3] Expression of p53 in renal carcinoma cells is independent of pVHL
    Stickle, NH
    Cheng, LS
    Watson, IR
    Alon, N
    Malkin, D
    Irwin, MS
    Ohh, M
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 578 (1-2) : 23 - 32
  • [4] Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma
    Baytekin, Firat
    Tuna, Burcin
    Mungan, Ugur
    Aslan, Guven
    Yorukoglu, Kutsal
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (05) : 502 - 507
  • [5] Characterization and apoptotic effect of copper nanoparticles biosynthesized fromZiziphus zizyphusleaf on human renal cell carcinoma A498 cells
    Li, Xianduo
    Tang, Guanbao
    Guo, Xuewen
    Men, Tongyi
    APPLIED NANOSCIENCE, 2021, 11 (01) : 139 - 148
  • [6] p53 expression in correlation to clinical outcome in patients with renal cell carcinoma
    Ljungberg, B
    Bozoky, B
    Kovacs, G
    Stattin, P
    Farrelly, E
    Nylander, K
    Landberg, G
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2001, 35 (01): : 15 - 20
  • [7] Gelsolin, NF-κB, and p53 expression in clear cell renal cell carcinoma: Impact on outcome
    Kankaya, Duygu
    Kiremitci, Saba
    Tulunay, Ozden
    Baltaci, Sumer
    PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (07) : 505 - 512
  • [8] Evaluation of p53 protein expression in renal cell carcinoma: Comparison of two antibodies
    Walsh, CJB
    Kay, EW
    Lynch, T
    Walsh, M
    Milburn, C
    McLean, PA
    Murphy, D
    Donovan, M
    Leader, MB
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 1996, 53 (03) : 179 - 181
  • [9] Characterization and apoptotic effect of copper nanoparticles biosynthesized from Ziziphus zizyphus leaf on human renal cell carcinoma A498 cells
    Xianduo Li
    Guanbao Tang
    Xuewen Guo
    Tongyi Men
    Applied Nanoscience, 2021, 11 : 139 - 148
  • [10] Paclitaxel/Taxol® sensitivity in human renal cell carcinoma is not determined by the p53 status
    Reinecke, P
    Kalinski, T
    Mahotka, C
    Schmitz, M
    Déjosez, M
    Gabbert, HE
    Gerharz, CD
    CANCER LETTERS, 2005, 222 (02) : 165 - 171
12345